July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Survey of TREATment for Diabetic Macular Edema (STREAT-DME) Study: Results by treatment options from real world data in Japan
Author Affiliations & Notes
  • Daisuke Muramatsu
    Ophthalmology, Tokyo Medical University, Shinjuku-ku, TOKYO, Japan
  • Masahiko Shimura
    Tokyo Medical University, Hachioji Medical Center, Hachioji, Japan
  • Shigehiko Kitano
    Diabetes Center, Tokyo Women's Medical University, Tokyo, Japan
  • Taiji Sakamoto
    Kagoshima University, Kagoshima, Japan
  • Footnotes
    Commercial Relationships   Daisuke Muramatsu, Alcon (F), Bayer (F); Masahiko Shimura, Alcon (F), Bayer (F), Wakamoto Pharmaceutical (C); Shigehiko Kitano, Novartis (F); Taiji Sakamoto, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1895. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Daisuke Muramatsu, Masahiko Shimura, Shigehiko Kitano, Taiji Sakamoto; Survey of TREATment for Diabetic Macular Edema (STREAT-DME) Study: Results by treatment options from real world data in Japan. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1895.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : In the treatment of Diabetic Macular Edema (DME), a multicenter retrospective survey of a 2-tear treatment course in clinical practice has been conducted. Here, we report about a statistical analysis in terms of Visual Acuity (VA) from the view point of comparing the treatment option with or without anti-VEGF therapy

Methods : Based on clinical records, 1172 treatment naïve DME eyes which had been started interventional treatment from 2010 to 2014 for 2 years at 18 domestic facilities were registered. The VA, Central Retinal Thickness (CRT) and the required number of each intervention (anti-VEGF drugs, corticosteroid, macular photocoagulation (MPC), Vitrectomy) during the clinical course were extracted.

Results : Of total 1172 eyes, 252 (21.5%) had anti-VEGF monotherapy (Group 1), 500 (42.7%) had combination therapy with anti-VEGF drugs (Group 2), and 420 (35.8%) had alternative therapy without anti-VEGF drugs (Group 3). The improvement of VA in each group was 0.12±0.35, 0.04±0.37, and 0.05±0.34, respectively. Mean required number of anti-VEGF drug injections was 4.3 times in Group 1 and 3.5 times in Group 2. In group 2 of 500 eyes, 311 eyes (62,2%) had local administration of corticosteroid, 258 eyes (50.2%) had MPC, and 172 eyes (34.4%) had vitrectomy. While in group 3 of 420 eyes, 272 eyes (64.8%) had corticosteroid, 231 eyes (55.0%) had MPC, and 150 eyes (23.8%) had vitrectomy.

Conclusions : From this real-world data, anti-VEGF drugs had been adopted for ≈60% of DME eyes for 2 years, and obtained better visual prognosis.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.